Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis InfectionsFebruary 24, 2014 8:01 am | News | Comments
Cellceutix Corporation has selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of...
The FDA has approved the first generic versions of Cymbalta (duloxetine delayed-release capsules...
Dr. Reddy’s Laboratories announced today that Azacitidine for Injection 100 mg/vial, a...
Dr. Reddy's Laboratories Ltd. said Tuesday its net income climbed 67 percent in the fiscal fourth quarter. The company said it earned 5.7 billion rupees ($104 million), or 60 cents per U.S. share. Its revenue grew 26 percent to 33.4 billion rupees ($611 million)
Dr. Reddy’s Laboratories today announced plans to relocate their North America Headquarters and establish a R&D Center in Princeton, New Jersey. Dr. Reddy’s anticipates relocation to the office facility at 107 College Road East by the end of the summer of 2013 after the renovations to the facility are completed.
Dr. Reddy’s Laboratories announced today that it has launched Zenatane™ (Isotretinoin Capsules USP) in 20 mg and 40 mg, a therapeutically equivalent generic version of Accutane® (Isotretinoin Capsules USP) in the US market on March 28, 2013 following the approval by the United States Food & Drug Administration (USFDA)
Dr. Reddy's Laboratories Ltd. said Thursday its fiscal third-quarter earnings fell 26 percent compared to the same quarter last year, when a generic version of the antipsychotic Zyprexa boosted its North American sales. The Indian company reported net income of $69 million, or 40 cents per share, in the three months that ended Dec. 31.
Dr. Reddy’s Laboratories Ltd. today announced that Umang Vohra, who was the CFO of the company for the past four years, will take over the role of Executive Vice-President and Head of North America Generics Business from January 2013.
Dr. Reddy's Laboratories Ltd. and Merck Serono Announce Collaboration to Develop and Commercialize BiosimilarsJune 6, 2012 4:02 am | News | Comments
Dr. Reddy's Laboratories Ltd. and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions.
Dr. Reddy's Laboratories said Monday it has terminated a proposed deal to buy J.B. Chemicals & Pharmaceuticals' prescription products business in Russia and the Commonwealth of Independent States, as reported on NASDAQ.
Federal regulators approved a generic version of a blood-clot treatment made by Dr. Reddy's Laboratories, the company said Wednesday.
POZEN Inc. and AstraZeneca have filed a lawsuit against Dr. Reddy's Laboratories (Dr. Reddy's) in the United States District Court for the District of New Jersey, for infringement of U.S. Patent No. 6,926,907 relating to VIMOVO(TM) (naproxen / esomeprazole magnesium) delayed-release tablets.